⚡ 𝐔𝐏𝐃𝐀𝐓𝐄: $ImmunityBio(IBRX.US) ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain BCG
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ ImmunityBio signs exclusive U.S. agreement with 𝐉𝐚𝐩𝐚𝐧 𝐁𝐂𝐆 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲.➤ Deal targets long-standing 𝐔.𝐒. 𝐁𝐂𝐆 𝐬𝐡𝐨𝐫𝐭𝐚𝐠𝐞 in bladder cancer treatment.➤ Agreement covers development and commercialization of 𝐓𝐨𝐤𝐲𝐨-𝟏𝟕𝟐 𝐁𝐂𝐆.➤ Phase III SWOG S1602 study showed 𝐧𝐨𝐧-𝐢𝐧𝐟𝐞𝐫𝐢𝐨𝐫𝐢𝐭𝐲 versus TICE BCG.➤ Tokyo strain achieved 𝟔𝟒% 𝟓-𝐲𝐞𝐚𝐫 high-grade recurrence-free survival.➤ Product remains 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 and unapproved by the FDA in the U.S.➤ ImmunityBio plans FDA engagement and 𝐁𝐋𝐀 submission using S1602 data.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments